Tivic Health Systems Inc

TIVC

$1.23

Closing

▲2.50%

1D

▼-32.79%

YTD

Market cap

$1.83M

52 week high

$23.79

52 week low

$1.01

Volume

8,282

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$1.83M

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

1

P/E

Operating Margin

-624.11%

Beta

Revenue Growth (Annual)

46.38%

52 week high

$23.79

52 week low

$1.01

Div. Yield

%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Tivic Health Systems, Inc. is a commercial-stage health tech company advancing the field of bioelectronic medicine. The Company’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Its non-invasive and targeted approach to the treatment of inflammatory chronic health conditions is intended to give consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. The Company’s first commercial product, ClearUP, is an FDA approved handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and available through online retailers and commercial distributors. ClearUP is sold in the U.S. directly to consumers on various platforms and through reseller channels. The Company is also focused on its intellectual property (IP) portfolio and research programs related to vagus nerve stimulation to expand its applications in non-invasive bioelectronic medicine.